Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 2

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 2
---
5.

1

Adopt a two-pronged patent
strategy. We are pursuing a two-pronged product development strategy that will seek to solidify our existing IP to prevent competition
and expand our IP suite into related therapeutic areas. We are confident that our core in-licensed IP (see the section entitled “Intellectual
Property”) and IP generated by the Company will allow us both freedom-to-operate and provide robust protection from outside competition
across all of our drug platforms. We will continue to invest in expanding our patent suite. We will also seek to further strengthen our
IP position by looking to in-license IP related to our focus on the innate immune system. All of our products are biologic products eligible
for Biologic Exclusivity after first approval. In the US, Biologic Exclusivity currently allows for 12 years of marketing exclusivity.

Provide clear value propositions
to third-party payors to merit reimbursement for our product candidates. We are designing our clinical development programs to demonstrate
compelling, competitive advantages to patients and prescribers, and to demonstrate value propositions to third-party payors. We believe
the use of INKmune patients with a high risk of tumor progression and death from tumor should safely prolong survival, improve the patient’s
quality of life and decrease the total cost of care for patients with these lethal malignancies. For example, cancer patients relapse
frequently. Each relapse requires a complex treatment regimen that has decreasing benefits. Treatment with INKmune as an out-patient may
provide a more durable remission and limit the need for treatment-associated hospitalizations. At the patient level, we believe INKmune,
if approved, should improve survival and quality of life. At the payor level, we believe INKmune, if approved, should provide more predictable
costs and outcomes. Additional therapies are need for treatment of Alzheimer’s disease are needed for medical, societal and economic
reasons. The cost of Alzheimer’s disease to the government is large and growing. Recently approved therapies that target amyloid
have a modest impact on disease progression and are difficult to use due to side-effects in some patients. The cost of AD to families
and care givers is real and burdensome. We believe treatment of dementia patients with XPro, including Alzheimer’s disease, may
provide a strategy to alter the costly dynamic of this disease in society today. RDEB is a lethal and debilitating disease in children
that requires life-long care-g